Biotricity Reports Second Quarter Fiscal 2027 Results
Globe Newswire•20/11/2026•08:35 ET
0
Key Highlights
- ➤Q2 revenue increased 11.5% to $4.33 million
- ➤Technology fee revenue rose 13.3% to $3.98 million
- ➤Gross margin improved to 83.3% from 81.9%
- ➤Income from operations increased 23.7% to $339 thousand
- ➤National distribution pilot offers partner-funded expansion with a 30% distribution margin
Expert Statements
Waqaas Al-Siddiq, Founder and CEO of Biotricity
“Our second quarter delivered year-over-year growth in technology fee revenue, a higher gross margin and operating leverage. Revenue grew 11.5%, gross margin expanded to 83.3% and income from operations rose 23.7%, as gross profit growth outpaced higher operating expenses, including the timing of research and development activities.”
Revenue up 11.5%, gross margin 83.3% and income from operations up 23.7%.
REDWOOD CITY, CA , Nov. 20, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY) ("Biotricity" or the "Company"), a medical technology company providing remote cardiac monitoring solutions, announced its financial results for the second quarter of fiscal 2027, ended September 30, 2026.
Get started
Create a free account to read the full story.
